Seeking Alpha

Navidea Biopharmaceuticals (NAVB -1.5%) says results from a clinical trial of NAV4694 in healthy...

Navidea Biopharmaceuticals (NAVB -1.5%) says results from a clinical trial of NAV4694 in healthy subjects and those with diagnosed forms of dementia demonstrated imaging characteristics nearly identical to those of an acknowledged benchmark, gold-standard amyloid imaging agent, 11C-labeled Pittsburgh Compound-B. The authors believe these results show that NAV4694 may be useful in the early and differential diagnosis of Alzheimer’s disease.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs